Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440648 · ClinicalTrials.gov registry record · Phase 2
Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00440648 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 80 participants.
The verdict
NCT00440648, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment periods and a two-week Washout Period. Patients are assigned randomly (1:1) to one of two treatment sequences: sevelamer carbonate for eight weeks followed by sevelamer hydrochloride for eight weeks or sevelamer hydrochloride for eight weeks followed by sevelamer carbonate for eight weeks
Interventions
- DRUG sevelamer carbonate, sevelamer hydrochloride
- DRUG sevelamer hydrochloride, sevelamer carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440648
The ClinicalTrials.gov registry entry for NCT00440648 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sevelamer carbonate, sevelamer hydrochloride is the first listed.
NCT00440648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00440648 about?
NCT00440648 is a clinical study titled "Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate". This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment periods and a two-week Washout Period. Patients are assigned randomly (1:...
What is the current status of trial NCT00440648?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-03. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00440648?
The interventions under investigation include: sevelamer carbonate, sevelamer hydrochloride (DRUG), sevelamer hydrochloride, sevelamer carbonate (DRUG).
Who is sponsoring clinical trial NCT00440648?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.